The Monthly Roundup page provides investors with a single destination to view all fund updates, portfolio activity, media coverage, and additional insights, conveniently summarised in one place.
The Monthly Roundup page provides investors with a single destination to view all fund updates, portfolio activity, media coverage, and additional insights, conveniently summarised in one place.
A fortnightly call where Amati Managers aim to share opinions on key events over the previous weeks. 10 – 15 minutes of concise comment at 8:45am every second Tuesday.
In this edition of Amati Insights, Mikhail Zverev and Graeme Bencke discuss the key themes emerging from two major pharmaceutical industry conferences: CPHI and the Festival of Biologics.
The conversation explores how artificial intelligence is transforming drug discovery by helping researchers identify promising drug candidates more quickly and efficiently. As AI expands the number of molecules entering development, demand is also increasing for laboratory automation, clinical trial services and life sciences tools that support the testing and scaling of new treatments.
Mikhail and Graeme also examine the continued shift towards biologic medicines, including antibody therapies, radiopharmaceuticals, cell therapies and gene therapies. These advances are driving greater complexity in drug manufacturing and creating opportunities for companies involved in bioprocessing, laboratory technologies and healthcare automation.
The discussion further considers the growing importance of pharmaceutical logistics, supply-chain resilience and specialised distribution networks as biologic therapies become a larger part of global healthcare markets.
Watch the latest Amati Insights call as Mikhail and Graeme share their latest thinking on healthcare innovation, the accelerating impact of AI across the pharmaceutical industry, and the long-term investment opportunities they see emerging throughout the life sciences ecosystem.
Machine sensing is becoming an increasingly important enabler of physical AI, robotics and industrial automation. As machines become more intelligent, they require advanced sensing capabilities to understand and interact with the world around them. While machine vision remains a core technology, the industry is evolving beyond traditional cameras to incorporate 3D sensing, infrared imaging, hyperspectral imaging and AI-powered recognition systems.
In this Amati Insights discussion, Amati fund managers Mikhail Zverev and Graeme Bencke share their latest observations from Vision 2026, one of the leading trade shows for the machine vision industry. They explore how advances in machine sensing are creating new opportunities across manufacturing, logistics, robotics, life sciences, agriculture and defence, and discuss the investment implications of these long-term technology trends.
Warning: Capital at risk. Professional Investors Only.
* Registration is required to view this article
| Date | Description. |
| 30/10/2026 | Mikhail Zverev of the WS Amati Global Innovation Fund, shared his views with Dow Jones Newswires on changing investor sentiment towards AI spending following the latest round of big-tech earnings, in an article published by Morningstar.” |
| 29/10/2026 | Trustnet featured the WS Amati Global Innovation Fund in its analysis of top-performing global funds finding opportunities beyond the market’s dominant mega-cap stocks.” |
| 26/10/2026 | Amati CEO Dr Paul Jourdan shared his views with FundCalibre on the value available within UK smaller companies and the increasing interest from international investors, in an article published by Professional Paraplanner.” |
| 16/10/2026 | Amati CEO Dr Paul Jourdan shared his views with Investment Week as part of its latest ‘Big Question’, exploring what reduced fiscal headroom in the Budget could mean for markets and investors.” |
| 15/10/2026 | Mikhail Zverev of the WS Amati Global Innovation Fund, shared his views with Dow Jones Newswires on the impact of higher interest rates and the cost of capital on investment in artificial intelligence.” |
| 15/10/2026 | The WS Amati Strategic Metals Fund was highlighted by Trustnet as one of the most-researched funds in the IA Commodity/Natural Resources sector, as investor interest in the sector continues to grow.” |
| 15/10/2026 | Darius McDermott of FundCalibre highlights the WS Amati Strategic Metals Fund in Portfolio Adviser as one way for investors to gain exposure to the growing investment in electrification and the global energy transition.” |
| 14/10/2026 | Graeme Bencke of the WS Amati Global Innovation Fund shares his views with FundCalibre on finding less well-known areas of innovation in well-valued businesses with strong and resilient business models.” |
| 06/10/2026 | Gregor Paterson, co-manager of the WS Amati UK Listed Smaller Companies Fund, shared his views with Trustnet on businesses whose value lies in their specialist expertise and client relationships, despite concerns around AI disruption.” |
Amati Global Investors Limited
This website is not intended to provide investment, tax or legal advice and none of its content should be construed as a recommendation to buy, sell, or hold, any security, investment product or service. You are solely responsible for determining whether any investment is appropriate for you, based on your investment objectives, financial circumstances and risk tolerance. If you are unsure about the meaning of any information provided, or if you are uncertain as to how to proceed, please consult an independent financial adviser. If you do not have a financial adviser, please contact, where information on finding one can be obtained.
Any research or analysis contained in this website has been prepared or obtained by Amati for its own use. While sources of information are believed to be reliable, no guarantee, warranty or representation is given as to their accuracy or completeness. Investment markets and conditions can change rapidly and as such any views expressed should not be taken as statements of fact nor should reliance be placed on these views when making investment decisions.
By checking the box and proceeding to the website you have confirmed that you have read and understood the information set out below and that you fully understand the risks involved in an investment of this nature.
WS Amati UK Listed Smaller Companies Fund
WS Amati Strategic Metals Fund
WS Amati Global Innovation Fund
Issued by: Amati Global Investors Limited, 8 Coates Crescent, Edinburgh EH3 7AL. Registered in Scotland (company no. SC199908). FCA reference number: 198024
Amati Global Investors is authorised and regulated by the Financial Conduct Authority.
8 Coates Crescent
Edinburgh
EH3 7AL
